SUBSCRIBE

Breaking News on Global Pharmaceutical Technology & Manufacturing

Ingredients: Top Headlines

Merck KGaA biopharma division to make small molecule drugs in China

Nantong, China where Merck Serono's new site will open in 2017

29-Aug-2014 - Biopharmaceutical firm Merck Serono will make small molecule drugs at the new plant it is building in China according to a company spokeswoman, who told us the firm will supply both local and international markets.

Related news

News in brief

GSK: GM yeast breakthrough won't kill off poppy-based opium

28-Aug-2014 - Poppies will continue to be the main source of industrial opiates long-term according to GSK, despite a recent breakthrough in efforts to produce it in GM yeast.

DEA approves manufacture of GHB at Patheon Cincinnati plant

26-Aug-2014 - Patheon has received approval from the DEA to bulk manufacture the schedule I product Gamma Hydroxybutyric Acid (GHB) from its facility in Cincinnati, Ohio.

EMD Millipore to supply Samsung's Yervoy plant in 10-year deal

26-Aug-2014 - EMD Millipore has been contracted to supply raw materials to the Samsung Biologics plant where ingredients for BM-S’ anticancer monoclonal antibody Yervoy (ipilimumab) are made.

EFPIA, EGA take issue with EMA’s guidance on stability data for APIs

25-Aug-2014 - EFPIA (European Federation of Pharmaceutical Industries and Associations) and EGA (European Generics Association) have released comments suggesting specific changes to the EMA’s draft guidance on stability data for manufacturing changes.

Claris gets MHRA OK for injectables plant

21-Aug-2014 - Indian manufacturer Claris Lifesciences has had its injectable drug manufacturing facility in Ahmedabad approved by the UK MHRA.

Macfarlan Smith fined $12,000 after accident at API plant

21-Aug-2014 - Opiate API manufacturer Macfarlan Smith has been fined £12,000 for failing to ensure the safety of an employee injured at its plant in Scotland in 2011.

US FDA 'stamp of approval' testament to WuXi's growth in APIs

19-Aug-2014 - WuXiPharmaTech has received US FDA approval to manufacture an API for a commercial drug from a plant in Shanghai.

Ingredients: Featured news

Spotlight

SCM's woes part of UK-wide aseptic slowdown, says ex-owner

SCM's woes part of UK-wide aseptic slowdown, says ex-owner

GMP failures at an aseptic plant owned by SCM Pharma are part of a wider industry trend...

Boehringer aims to cut German costs 15% as H1 sales fall

Boehringer Ingelheim aims to cut German costs 15% as revenues drop

German jobs are safe despite a programme that will cut the cost of operations by 15%, Boehringer...

WHO: Data from use of unapproved Ebola drugs should be shared

WHO: Data from use of unapproved Ebola drugs should be shared

Efficacy and safety data from use of unapproved Ebola virus treatments should be shared according to an...

THC may reduce tumor size? mouse study investigates

THC may reduce tumor size? mouse study investigates

A previously unknown signaling platform may be responsible for the success of the main psychoactive ingredient in...

India’s CDSCO outlines procedures for state manufacturer inspections

India’s CDSCO outlines procedures for state inspections of manufacturers

In order to ensure uniformity on the state and federal levels, India’s CDSCO (Central Drugs Standard Control...

Roche re-enters RNAi space with $250m Santaris acquisition

Roche re-enters gene silencing space with $250m LNA acquisition

Roche has renewed its interest in gene silencing drugs, paying $250m (€187m) for Santaris Pharma including its...

Key Industry Events

 

Access all events listing

Our events, Events from partners...